Sanofi lowers price of Zaltrap after Sloan-Kettering refusal to use it


Sanofi is lowering the price of ziv-aflibercept (Zaltrap) for previously treated colorectal cancer by half after physicians at Memorial Sloan Kettering Cancer Center (MSKCC) said that they would not use the drug, according to The New York Times.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.